PolyPeptide attracts takeover interest from EQT, KKR, Bloomberg News reports
Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including EQT AB and KKR & Co. , Bloomberg News reported on Friday, citing people with knowledge of the matter.
Open original source